BR112019006127A2 - anticorpos anti-rankl e usos destes - Google Patents

anticorpos anti-rankl e usos destes

Info

Publication number
BR112019006127A2
BR112019006127A2 BR112019006127A BR112019006127A BR112019006127A2 BR 112019006127 A2 BR112019006127 A2 BR 112019006127A2 BR 112019006127 A BR112019006127 A BR 112019006127A BR 112019006127 A BR112019006127 A BR 112019006127A BR 112019006127 A2 BR112019006127 A2 BR 112019006127A2
Authority
BR
Brazil
Prior art keywords
antibodies
rankl antibodies
bind
cancer
agents
Prior art date
Application number
BR112019006127A
Other languages
English (en)
Inventor
Ihor Korytko Andrew
H Obungu Victor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112019006127A2 publication Critical patent/BR112019006127A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos e métodos de usar estes anticorpos são fornecidos que se ligam a ativador do receptor humano e de camundongo de ligante de fator capa-b nuclear, os ditos anticorpos são úteis como agentes para tratar condições associadas com transtornos relacionados aos ossos ou anormalidades esqueléticas causadas por câncer.
BR112019006127A 2016-10-28 2017-10-20 anticorpos anti-rankl e usos destes BR112019006127A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414217P 2016-10-28 2016-10-28
PCT/US2017/057543 WO2018080914A1 (en) 2016-10-28 2017-10-20 Anti-rankl antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112019006127A2 true BR112019006127A2 (pt) 2019-06-18

Family

ID=60191583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006127A BR112019006127A2 (pt) 2016-10-28 2017-10-20 anticorpos anti-rankl e usos destes

Country Status (12)

Country Link
US (1) US10913799B2 (pt)
EP (1) EP3532501A1 (pt)
JP (3) JP7246306B2 (pt)
KR (1) KR20190052137A (pt)
CN (1) CN109890845B (pt)
AU (1) AU2017351026A1 (pt)
BR (1) BR112019006127A2 (pt)
CA (1) CA3038850A1 (pt)
EA (1) EA201990557A1 (pt)
IL (1) IL266059A (pt)
MX (1) MX2019004862A (pt)
WO (1) WO2018080914A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11492386B2 (en) * 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
EP1283721A4 (en) * 2000-05-26 2004-07-07 Smithkline Beecham Corp ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
WO2009105934A1 (zh) * 2008-02-27 2009-09-03 上海先导药业有限公司 抗人rankl单克隆抗体
AR073072A1 (es) * 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CN105189551B (zh) * 2013-03-14 2021-03-05 埃派斯进有限公司 抗-rankl抗体及其使用方法
WO2015030701A1 (en) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Fully human antibodies against human rankl
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3085709B1 (en) * 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
JP6567083B2 (ja) * 2015-05-18 2019-08-28 イーライ リリー アンド カンパニー 抗ｄｋｋ−１−抗ｒａｎｋｌ二重特異性抗体化合物
US11492386B2 (en) * 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds

Also Published As

Publication number Publication date
JP2024073462A (ja) 2024-05-29
JP7246306B2 (ja) 2023-03-27
IL266059A (en) 2019-06-30
US20190284289A1 (en) 2019-09-19
EP3532501A1 (en) 2019-09-04
WO2018080914A1 (en) 2018-05-03
US10913799B2 (en) 2021-02-09
EA201990557A1 (ru) 2019-09-30
AU2017351026A1 (en) 2019-03-21
CN109890845A (zh) 2019-06-14
CA3038850A1 (en) 2018-05-03
KR20190052137A (ko) 2019-05-15
MX2019004862A (es) 2019-08-12
JP2020500836A (ja) 2020-01-16
JP2022058436A (ja) 2022-04-12
CN109890845B (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
BR112018008867A8 (pt) anticorpos que se ligam especificamente a pd-1 e seus usos
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112017024555A2 (pt) moduladores de ccr2
CO2017002719A2 (es) Anticuerpos anti-glucagón
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112018007017A2 (pt) polipeptídeos
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112017006464A2 (pt) bloqueio de cd73
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
BR112016030690A2 (pt) moduladores do receptor de arila e métodos de fabricar e usar os mesmos
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112012028764A2 (pt) anticor-pos antifgfr2
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
BR112016025470A2 (pt) ?hdl terapêutico?
BR112016019825A2 (pt) anticorpos do fator bb do complemento

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]